NasdaqGM - Nasdaq Real Time Price USD

Immuneering Corporation (IMRX)

1.2900

+0.1000

+(8.40%)

At close: May 1 at 4:00:01 PM EDT

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Of

GlobeNewswire 29 days ago

IMRX
+8.40%
Immuneering Corporation Announces Grant of Inducement Award

CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D., Ph.D., was named Chief Medical Officer of the Company. In connection with the commencement of Dr. Matushanky’s employment, on March 21, 2025, Dr. Matushanky was granted an option to purchase 118,000 s

GlobeNewswire last month

IMRX
+8.40%
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for po

GlobeNewswire last month

IMRX
+8.40%
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Ig

GlobeNewswire last month

IMRX
+8.40%
Immuneering Slides As Insider Purchases Lose Another US$186k

The recent 10% drop in Immuneering Corporation's ( NASDAQ:IMRX ) stock could come as a blow to insiders who purchased...

Simply Wall St. last month

IMRX
+8.40%
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

- Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1 – CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today

GlobeNewswire 2 months ago

IMRX
+8.40%
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zesk

GlobeNewswire 2 months ago

IMRX
+8.40%
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

As the S&P 500 nears record highs, fueled by a surge in AI stocks and robust earnings reports, investors are keenly observing opportunities across various market segments. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Simply Wall St. 3 months ago

IMRX
+8.40%

PXLW
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Nearly $14M in net proceeds raised in January 2025 through utilization of Company’s ATM - CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize

GlobeNewswire 3 months ago

IMRX
+8.40%
Why Is Immuneering Stock Trading Higher On Tuesday?

On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a

Benzinga 3 months ago

IMRX
+8.40%
Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates

Immuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate I

PREMIUM
MT Newswires 3 months ago

IMRX
+8.40%
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial dat

GlobeNewswire 3 months ago

IMRX
+8.40%
Aadi Bioscience Leads 3 Promising US Penny Stocks

As the U.S. stock market navigates a challenging week marked by encouraging inflation data yet overall losses, investors are exploring diverse opportunities to mitigate risk and capitalize on potential gains. Penny stocks, often associated with smaller or newer companies, continue to attract attention due to their potential for significant returns when backed by strong financial health. Despite being considered a niche area of investment today, these stocks can offer intriguing opportunities...

Simply Wall St. 4 months ago

AADI

IMRX
+8.40%

QD
Immuneering Launches Pancreatic Cancer Advisory Board

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced th

GlobeNewswire 4 months ago

IMRX
+8.40%
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to

GlobeNewswire 4 months ago

IMRX
+8.40%
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

Benzinga 4 months ago

IMRX
+8.40%

FOLD

IMCR
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX

GlobeNewswire 4 months ago

IMRX
+8.40%
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Parti

GlobeNewswire 5 months ago

IMRX
+8.40%
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

As the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and S&P 500 showing gains, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond well-known names. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when...

Simply Wall St. 5 months ago

IMRX
+8.40%

WDH

ANTX
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer - - Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End - - Cash Runway into Fourth Quarter 2025 - CAMBRIDGE,

GlobeNewswire 5 months ago

IMRX
+8.40%

Performance Overview

Return	IMRX	S&P 500 (^GSPC)
YTD	-41.36%	-4.72%
1-Year	-15.69%	+11.67%
3-Year	-74.04%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immuneering Corporation (IMRX)

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Slides As Insider Purchases Lose Another US$186k

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Aadi Bioscience Leads 3 Promising US Penny Stocks

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Performance Overview